SYNLOGIC, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.87 USD | +0.54% |
|
0.00% | -51.43% |
| 03-21 | Synlogic, Inc. Announces Board Changes | CI |
| 03-21 | North American Morning Briefing : Investors -2- | DJ |
| Sales 2024 * | 263K 21.08M | Sales 2025 * | 4.48M 358M | Capitalization | 21.78M 1.74B |
|---|---|---|---|---|---|
| Net income 2024 * | -24M -1.92B | Net income 2025 * | -43M -3.44B | EV / Sales 2024 * | -21.3 x |
| Net cash position 2024 * | 27.4M 2.19B | Net cash position 2025 * | 67.4M 5.4B | EV / Sales 2025 * | -10.2 x |
| P/E ratio 2024 * |
-0.74
x | P/E ratio 2025 * |
-0.49
x | Employees | 6 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.33% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +0.54% | ||
| Current month | +4.47% | ||
| 1 month | +5.06% | ||
| 3 months | -48.06% | ||
| 6 months | -1.06% | ||
| Current year | -51.43% |
1 week
1.79
1.96
1 month
1.701.96
Current year
1.555.12
1 year
1.5510.20
3 years
1.5568.10
5 years
1.55150.15
10 years
1.55345.00
| Managers | Title | Age | Since |
|---|---|---|---|
Antoine Awad
CEO | Chief Executive Officer | 44 | 30/09/18 |
Mary Dooley
DFI | Director of Finance/CFO | 43 | 31/05/18 |
Brendan St Amant
LAW | General Counsel | - | 30/06/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Shea
BRD | Director/Board Member | 72 | 27/08/17 |
Peter Barrett
CHM | Chairman | 71 | 27/08/17 |
| Director/Board Member | 64 | 30/09/12 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 1.87 | +0.54% | 3,846 |
| 25/04/24 | 1.86 | -0.53% | 4,043 |
| 24/04/24 | 1.87 | -2.09% | 18,903 |
| 23/04/24 | 1.91 | +3.80% | 66,030 |
| 22/04/24 | 1.84 | -1.60% | 21,787 |
Delayed Quote Nasdaq, April 26, 2024 at 09:30 pm
More quotes
Synlogic, Inc. is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases. The Company is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The Company's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. It designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Companyâs preclinical work includes additional metabolic disease research.
Calendar
08/05/2024
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
1.87
USD
Average target price
1
USD
Spread / Average Target
-46.52%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -51.43% | 21.78M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- SYBX Stock
